Poster 9
- Kelley Tangredi
- Jun 9, 2024
- 1 min read
Updated: Jun 27, 2024
Pooled safety assessments from the multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 trials of deuruxolitinib in adult patients with moderate-to-severe alopecia areata
Authors: Brett King; Maryanne Makredes Senna; Natasha A. Mesinkovska; Arash Mostaghimi; Colleen Hamilton; James Cassella

Poster 9

